Sunflower Pharmaceutical announced that the company's holding subsidiary, Sunflower Pharmaceutical Group Defill Co., Ltd., recently received a registration certificate for mesalazine enteric sustained-release granules issued by the State Drug Administration. The drug is a Class 3 prescription drug used to treat acute attacks of ulcerative colitis and maintain remission. This approval will enrich the company's “one old” strategic product pipeline and strengthen its competitive advantage in the field of drug use in the old chronic disease system. There is uncertainty about the scale of drug marketing, promotion and sales.

Sunflower Pharmaceutical announced that the company's holding subsidiary, Sunflower Pharmaceutical Group Defill Co., Ltd., recently received a registration certificate for mesalazine enteric sustained-release granules issued by the State Drug Administration. The drug is a Class 3 prescription drug used to treat acute attacks of ulcerative colitis and maintain remission. This approval will enrich the company's “one old” strategic product pipeline and strengthen its competitive advantage in the field of drug use in the old chronic disease system. There is uncertainty about the scale of drug marketing, promotion and sales.